ENGLISH · RESEARCH LIBRARY
Each entry shows the molecule's pharmacology, regulatory class, evidence grade and a concise English evidence boundary.
Class describes development/regulatory context; grade describes evidence strength, not which molecule is better.
Select 2–3 molecules to compare evidence, not treatment recommendations.
EVIDENCE VISUAL · Metabolic / GLP-1A GLP-1 receptor agonist with strong human and regulatory evidence, but approvals remain product-, population- and indication-specific.
EVIDENCE VISUAL · Metabolic / GLP-1A dual GIP/GLP-1 receptor agonist with strong clinical evidence; Mounjaro and Zepbound must be assessed as separate products and jurisdictions.
EVIDENCE VISUAL · Metabolic / GLP-1An investigational triple GIP/GLP-1/glucagon receptor agonist with Phase 2 and Phase 3 research, but no marketing authorisation established in the reviewed jurisdictions.
EVIDENCE VISUAL · Metabolic / GLP-1A long-acting amylin analogue under clinical development; combination and monotherapy evidence should not be conflated.
EVIDENCE VISUAL · Metabolic / GLP-1An investigational glucagon/GLP-1 receptor agonist studied in obesity and MASH; trial results are not the same as approval.
EVIDENCE VISUAL · Metabolic / GLP-1A glucagon/GLP-1 receptor agonist with jurisdiction-specific approval; status should not be transferred across countries or products.
EVIDENCE VISUAL · Metabolic / GLP-1A GLP-1 receptor agonist with product-specific type 2 diabetes and chronic weight-management evidence; Victoza and Saxenda indications are not interchangeable.
EVIDENCE VISUAL · Metabolic / GLP-1An amylin analogue with a narrowly bounded insulin-adjunct diabetes indication in the United States and a boxed warning for severe hypoglycaemia with insulin.
EVIDENCE VISUAL · Metabolic / GLP-1An MC4 receptor agonist authorised for narrowly defined genetic and hypothalamic obesity contexts; these approvals explicitly do not extend to general obesity.
EVIDENCE VISUAL · Metabolic / GLP-1A GLP-1 receptor agonist with short- and extended-release products for type 2 diabetes; formulation-specific labels and evidence must remain separate.
EVIDENCE VISUAL · Metabolic / GLP-1A long-acting GLP-1 receptor agonist fusion protein with type 2 diabetes and cardiovascular-outcomes evidence; this is not a general weight-management approval.
EDUCATIONAL DILUENT GUIDE
Understand bacteriostatic water, preservative-free sterile water, single-dose/multiple-dose labels and key DailyMed/FDA warnings—without preparation or administration instructions.
ANDROGEN EVIDENCE GUIDE
Separate testosterone from esters, blends, Testagen and supplier terms, with TRAVERSE, FDA labeling, safety and WADA context—without doses or administration protocols.
ANABOLIC STEROIDS EVIDENCE MAP
Classify testosterone, nandrolone, trenbolone, DHT-derived and boldenone agents while separating HGH, SARMs, clenbuterol and hormone-modifying medicines—without cycles, doses or injection protocols.
SARM EVIDENCE GUIDE
Review ostarine, ligandrol, RAD140, andarine and YK-11 while separating commonly misclassified MK-677, cardarine and SR9009, with FDA and WADA boundaries.
IDENTITY NOTICES · NOT EVIDENCE PROFILES
These notices are public, but the exact products remain unidentified. They are separate from Evidence Profiles and excluded from their counts, rankings and comparison filters.
The name FOXO4 does not establish whether this item is the FOXO4 protein, a FOXO4-DRI peptide or another material. This page documents an unresolved identity, not a verified senolytic or anti-aging product.
COCK BOMBS is a product name with no verified ingredient information. The name alone does not identify an active molecule. This page assigns no formula, benefit or drug class.
Pure water does not specify grade, sterility, preservatives or an authorised purpose. It is not established as Sterile Water for Injection or Bacteriostatic Water.
Cagrilintide + semaglutide blend remains an unverified catalogue product. The supplier document claims cagrilintide and semaglutide, but that is not proof of composition, quality, safety or authorisation.
Retatrutide + cagrilintide blend remains an unverified catalogue product. The supplier document claims retatrutide and cagrilintide, but that is not proof of composition, quality, safety or authorisation.
Ipamorelin + tesamorelin blend remains an unverified catalogue product. The supplier document claims ipamorelin and tesamorelin, but that is not proof of composition, quality, safety or authorisation.
BPC-157 + TB-500 blend remains an unverified catalogue product. The supplier document claims BPC-157 and TB-500, but that is not proof of composition, quality, safety or authorisation.
CJC-related peptide + ipamorelin blend remains an unverified catalogue product. The supplier document claims a CJC-related peptide and ipamorelin, but that is not proof of composition, quality, safety or authorisation.
GHK-Cu + TB-500 + BPC-157 blend remains an unverified catalogue product. The supplier document claims GHK-Cu, TB-500 and BPC-157, but that is not proof of composition, quality, safety or authorisation.
BPC-157 + GHK-Cu + TB-500 + KPV blend remains an unverified catalogue product. The supplier document claims BPC-157, GHK-Cu, TB-500 and KPV, but that is not proof of composition, quality, safety or authorisation.
Acetic acid water 0.6% remains an unverified catalogue product. The supplier document claims water with an acetic-acid concentration claim, but that is not proof of composition, quality, safety or authorisation.
Lipo-C (LC120) remains an unverified catalogue product. The supplier document claims methionine, choline, carnitine and dexpanthenol, but that is not proof of composition, quality, safety or authorisation.
Lemon Bottle remains an unverified catalogue product. The supplier document claims a trade name without a reliable ingredient identity in the supplied document, but that is not proof of composition, quality, safety or authorisation.
LC216 blend remains an unverified catalogue product. The supplier document claims amino acids, methionine, inositol, choline and B vitamins, but that is not proof of composition, quality, safety or authorisation.
Lipo-C FAT BLASTER remains an unverified catalogue product. The supplier document claims carnitine, methionine, inositol, choline, vitamins and NADH, but that is not proof of composition, quality, safety or authorisation.
SUPER SHRED remains an unverified catalogue product. The supplier document claims carnitine, MIC blend, ATP, albuterol and vitamin B12, but that is not proof of composition, quality, safety or authorisation.
SUPER Human Blend remains an unverified catalogue product. The supplier document claims multiple amino acids, carnitine and NAC, but that is not proof of composition, quality, safety or authorisation.
Healthy Hair Skin Nails Blend remains an unverified catalogue product. The supplier document claims multiple B vitamins, choline, inositol, biotin and folic acid, but that is not proof of composition, quality, safety or authorisation.
Lipo-C FOCUS remains an unverified catalogue product. The supplier document claims ATP, Eria jarensis, carnitine, MIC blend, lidocaine and benzyl alcohol, but that is not proof of composition, quality, safety or authorisation.
Relaxation PM remains an unverified catalogue product. The supplier document claims GABA, melatonin, arginine and glutamine, but that is not proof of composition, quality, safety or authorisation.
Lipo Mino Mix remains an unverified catalogue product. The supplier document claims B vitamins, methionine, inositol, choline and carnitine, but that is not proof of composition, quality, safety or authorisation.
Immunological enhancement blend remains an unverified catalogue product. The supplier document claims glutathione, ascorbic acid and zinc sulfate, but that is not proof of composition, quality, safety or authorisation.
SHRED blend remains an unverified catalogue product. The supplier document claims carnitine, B vitamins, inositol, methionine and choline, but that is not proof of composition, quality, safety or authorisation.
GHK-Cu + glutathione blend remains an unverified catalogue product. The supplier document claims GHK-Cu, glutathione, histidine, glycine and NADH, but that is not proof of composition, quality, safety or authorisation.
Trenbolone acetate + trenbolone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone acetate and trenbolone enanthate, but that is not proof of composition, quality, safety or authorisation.
Three-ester trenbolone blend remains an unverified catalogue product. The supplier document claims three trenbolone esters, but that is not proof of composition, quality, safety or authorisation.
Trenbolone + drostanolone + testosterone propionate blend remains an unverified catalogue product. The supplier document claims trenbolone acetate, drostanolone propionate and testosterone propionate, but that is not proof of composition, quality, safety or authorisation.
Trenbolone + drostanolone + testosterone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone enanthate, drostanolone enanthate and testosterone enanthate, but that is not proof of composition, quality, safety or authorisation.
Trenbolone enanthate + drostanolone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone enanthate and drostanolone enanthate, but that is not proof of composition, quality, safety or authorisation.
Nandrolone phenylpropionate + nandrolone decanoate blend remains an unverified catalogue product. The supplier document claims nandrolone phenylpropionate and nandrolone decanoate, but that is not proof of composition, quality, safety or authorisation.
Drostanolone enanthate + drostanolone propionate blend remains an unverified catalogue product. The supplier document claims drostanolone enanthate and drostanolone propionate, but that is not proof of composition, quality, safety or authorisation.
Ripex-225 remains an unverified catalogue product. The supplier document claims no composition stated in the supplied line, but that is not proof of composition, quality, safety or authorisation.
These pages use noindex while identity remains unresolved. Visitors can still open and read them normally.
The site owner clarified the intended names as SLU-PP-332 (previously SLU-PP-322) and BPC-157 (previously unspecified BPC). These link to existing Evidence Profiles without duplicate entries. This naming correction does not verify supplier-product identity, quality, safety or authorisation.
READER INTEREST · ALL TIME
Most-opened Evidence Profiles and guides, combining Thai and English editions. Reading popularity is not evidence of safety, effectiveness or a recommendation to use a substance.
Loading reading statistics…
Counts page opens, not unique people or completed reads. Reloads may count again. Known bots are excluded where detectable; blocking scripts or cookies may reduce recorded counts. No individual reading history is stored.
IMPORTANT BOUNDARY
They do not provide prices, purchasing, dosing, injection protocols, diagnosis or individual treatment advice. Regulatory status may change and must be checked against current official records.
